Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma - Summary - MDSpire

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

  • By

  • Meera Mohan

  • Aniko Szabo

  • Heloise Cheruvalath

  • Anna Clennon

  • Vineel Bhatlapenumarthi

  • Anannya Patwari

  • Metodi Balev

  • Divaya Bhutani

  • Asis Shrestha

  • Sharmilan Thanendrarajan

  • Binod Dhakal

  • Maurizio Zangari

  • Anup Trikannad

  • Sruthi Vellanki

  • Samer Al-Hadidi

  • Suzanne Lentzsch

  • Frits van Rhee

  • Aishee Bag

  • Anita D’Souza

  • Nishi Shah

  • Rajshekhar Chakraborty

  • Mansi R. Shah

  • Carolina Schinke

  • April 23, 2025

  • 0 min

Share

Objective:

To understand the effect of primary IVIG replacement on clinical outcomes, specifically infection-free survival and other relevant clinical metrics, in recipients of BCMA-directed bispecific antibody therapy.

Key Findings:
  • 225 patients were included in the study, with 41% receiving primary IVIG prophylaxis. Statistical significance of findings should be included.
  • Infection-free survival (IFS) was evaluated using a 60-day landmark analysis, with results indicating a notable difference in infection rates.
  • Primary IVIG prophylaxis was associated with a reduction in the cumulative incidence of infections, with specific statistical data to support this.
Interpretation:

The study suggests that primary IVIG prophylaxis may improve infection-free survival in patients receiving BCMA-directed bispecific antibody therapy, addressing a significant risk of infections in this population.

Limitations:
  • Retrospective design may introduce bias, potentially affecting the reliability of the findings.
  • Limited data on the long-term effects of IVIG supplementation, which may influence the generalizability of the results.
  • Variability in infection prophylaxis protocols across institutions could lead to inconsistencies in outcomes.
Conclusion:

Primary IVIG prophylaxis could be beneficial in enhancing infection-free survival among patients undergoing BCMA-directed bispecific antibody therapy for multiple myeloma, suggesting a need for standardized prophylactic measures.

Original Source(s)

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

  • by Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Anannya Patwari, Metodi Balev, Divaya Bhutani, Asis Shrestha, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Anup Trikannad, Sruthi Vellanki, Samer Al-Hadidi, Suzanne Lentzsch, Frits van Rhee, Aishee Bag, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty, Mansi R. Shah, Carolina Schinke

  • April 23, 2025

Related Content

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min
Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China